3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Neoplasm Metastasis
6
Melanoma
5
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Solid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Synovitis, Pigmented Villonodular
1
Solid Tumours
1
Solid Tumour
1
Solid Tumors, KRAS Mutation
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostate Cancer Patients
1
Interventions
blinatumomab
5
midostaurin
2
Azacitidine
2
venetoclax
1
tisagenlecleucel
1
siremadlin
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
fludarabine phosphate
1
fludarabine
1
Zoledronic Acid
1
Vitamin D
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Midazolam
1
Idarubicin
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium
1
CD3 Complex
1
Anthracyclines
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm, Residual
×
Midazolam
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn